EntreMed, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said its annual meeting of stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals. The name change will occur June 16, with the rollout of a new web site, www.casipharmaceuticals.com.

"Changing our name is an important milestone, as it represents another step toward completing our company's transformation," said Ken K. Ren, Ph.D., EntreMed's CEO. "Our operations and strategic focus have evolved and today have little resemblance to our legacy years. Our name change is another step toward our mission to build a new and leading biopharmaceutical company targeting global markets with a focus on China."